Phase I/II Trial of Sodium Stibogluconate in Myelodysplastic Syndrome

Summary

Sodium stibogluconate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. This was originally designed as a phase I/II trial studying the side effects of sodium stibogluconate and how well it works in treating patients with myelodysplastic syndromes. Unfortunately, due to funding issues, the phase II portion was never conducted.

Timeline

Start

2009-07

Primary completion

2012-03

Completion

2013-05

Outcome

Outcome not reported

Stopped (Business): “Lack of funding, never moved into the phase II portion that was originally planned.”

Drugs

Indications